stoxline Quote Chart Rank Option Currency Glossary
  
Intra-Cellular Therapies, Inc. (ITCI)
128.67  0.71 (0.55%)    02-19 13:57
Open: 128.03
High: 128.75
Volume: 1,686,776
  
Pre. Close: 127.96
Low: 128
Market Cap: 13,670(M)
Technical analysis
2025-02-19 1:20:58 PM
Short term     
Mid term     
Targets 6-month :  150.38 1-year :  175.64
Resists First :  128.75 Second :  150.38
Pivot price 127.43
Supports First :  127.05 Second :  126
MAs MA(5) :  128.1 MA(20) :  127.36
MA(100) :  93.7 MA(250) :  80.38
MACD MACD :  5.4 Signal :  6.8
%K %D K(14,3) :  85 D(3) :  85.4
RSI RSI(14): 84.4
52-week High :  128.75 Low :  62.77
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ITCI ] has closed It is unclear right now based on current values. 87.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 128.27 - 128.78 128.78 - 129.22
Low: 126.47 - 127.11 127.11 - 127.66
Close: 126.87 - 127.9 127.9 - 128.79
Company Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Headline News

Wed, 19 Feb 2025
TimesSquare Capital Management LLC Buys 402,186 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Wed, 19 Feb 2025
Quantum Private Wealth LLC Sells 8,519 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Mon, 17 Feb 2025
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN

Mon, 13 Jan 2025
J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion - CNBC

Mon, 13 Jan 2025
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - Investopedia

Mon, 13 Jan 2025
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 106 (M)
Shares Float 104 (M)
Held by Insiders 3.2 (%)
Held by Institutions 96.9 (%)
Shares Short 1,600 (K)
Shares Short P.Month 1,980 (K)
Stock Financials
EPS -0.88
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.8
Profit Margin -14.1 %
Operating Margin -22.2 %
Return on Assets (ttm) -7.5 %
Return on Equity (ttm) -9.9 %
Qtrly Rev. Growth 39 %
Gross Profit (p.s.) 3.29
Sales Per Share 5.77
EBITDA (p.s.) -1.14
Qtrly Earnings Growth 0 %
Operating Cash Flow -62 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -147.96
PEG Ratio 0
Price to Book value 11.91
Price to Sales 22.28
Price to Cash Flow -220.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android